Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes the development of halo naevi, vitiligo, and diffuse alopecia areata in a 33-year-old woman undergoing tocilizumab therapy, suggesting a link between these conditions and cellular and humoral immune factors.

This narrative review reports that baricitinib, a first-generation JAK inhibitor, has shown effectiveness in treating alopecia areata and atopic dermatitis and holds promise for other chronic dermatoses, marking a significant advancement in dermatological immunotherapy according to the summarized findings.

In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.

Clofazimine may be effective for treating ashy dermatosis.

This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.

This systematic review reports that prophylactic minocycline and pyridoxine may reduce certain skin toxicities in cancer patients, but evidence quality for various interventions was limited and future research is needed.

In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.

In this animal study, cedrol treatment reduced chemotherapy-induced alopecia in mice by preventing hair follicle damage, while minoxidil did not prevent alopecia under similar conditions.

This study found that overexpressing PKCδ in transgenic mice did not reduce squamous cell carcinoma development induced by UV radiation, despite its effectiveness against TPA-promoted cancer in these mice.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This study found that both ciclosporin A and topical therapy were effective in reducing alopecia and scaling in dogs with idiopathic sebaceous adenitis, with evidence suggesting improved outcomes when both treatments are combined.

In this study, topical CUR61414 was effective in inhibiting basal cell carcinomas in mice, but no clinical activity was observed in human trials.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This study reported that a colistin sulfate-loaded nanoemulgel showed improved antimicrobial activity and skin permeability compared to a CS solution, suggesting a potential new approach for treating severe infections caused by multidrug-resistant bacteria.

Lowering the dose of cyclosporin caused hair loss that didn't improve even when the dose was increased again.

This report discusses a case of vesiculopustular eruption in a patient with ulcerative colitis, highlighting the effective use of ustekinumab for treatment and suggesting its consideration in similar cases of IBD-related skin lesions.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This study describes a case where immunochemotherapy, including chlorambucil and rituximab, successfully reversed agranulocytosis and other Waldenström's macroglobulinemia symptoms, indicating a possible connection between the two.

In this report, a 35-year-old female with palmoplantar pustulosis undergoing secukinumab treatment developed alopecia areata, a rare side effect attributed to paradoxical reactions with IL-17 inhibitors; switching to tofacitinib improved both conditions.

This study found that treating a murine model of systemic lupus erythematosus with early and optimally dosed mesenchymal stem cells effectively suppressed disease severity.

This study found that eliminating senescent cells using senolytic drugs effectively prevented and reversed paclitaxel-induced peripheral neuropathy in mice.

This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

This randomized controlled trial found that methotrexate, particularly when combined with low-dose prednisone, was effective in promoting hair regrowth in patients with alopecia areata totalis, with the combination treatment showing higher efficacy and faster results.